{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiad6cp7l7xttslp3v46bfidgzzk3mnyjltr66jmoxjpdfc6jlsmsu",
    "uri": "at://did:plc:fkyv2jw6fwu32arb3qovihu6/app.bsky.feed.post/3mn5xqznzjx72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigxaauw6rzxbsuencfwhentjokulqkgtqagluubis43wkd5whjbl4"
    },
    "mimeType": "image/jpeg",
    "size": 52176
  },
  "path": "/article/news/health/experimental-pill-pancreatic-cancer-treatment/507-3566d833-d519-4d66-aaeb-6c773551a7b0",
  "publishedAt": "2026-05-31T15:46:58.000Z",
  "site": "https://www.wfaa.com",
  "tags": [
    "health",
    "news",
    "nation-world",
    "cct-tracking",
    "syndication",
    "associatedpress"
  ],
  "textContent": "Researchers say the pill, daraxonrasib, works by blocking a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.",
  "title": "New pill nearly doubles survival time for pancreatic cancer patients"
}